Importance: Geographic atrophy (GA) is a progressing atrophy of the neuroretina with no treatment option.
INTRODUCTION
Geographic atrophy (GA) is a common neurodegenerative disease of the neuroretina. It represents a late stage of age-related macular degeneration (AMD) which is the most common cause of visual impairment among the elderly. 1 GA causes loss of central visual function through gradual atrophy of photoreceptors and the underlying retinal pigment epithelium (RPE). Despite comprehensive efforts, the underlying pathogenesis remains unclear. 2 The fate of cells in the transition between healthy and atrophic is unknown, and understanding the molecular changes and mechanisms is pivotal in order to develop intervention.
Fundus autofluorescence (FAF) is an in vivo spectrophotometry used clinically to evaluate RPE health and have become key in evaluating GA progression. In FAF, blue light excitation is used to excite fluorophores in the retina. The molecules then emit light that travel trough specialized filters and processed digitally to construct a FAF image. The signal is mainly derived from lipofuscin in the RPE. 3 Lipofuscin is constituted of lipids and proteins, biproducts from the visual cycle, and is associated with both aging and AMD. 4 In eyes with geographic atrophy, the dark absence of FAF signal indicates the atrophic lesion. In most cases of geographic atrophy, some degree of increased signal from RPE is observed in FAF imaging in the junctional zone of the atrophic lesion and in adjacent retina without atrophy. Several studies of the natural history of GA find that a high degree of hyperautofluorescence in relation to the atrophic area is an indicator of fast progression. 5, 6 The reason for hyperautofluorescence prior to cell death is unclear, but the increased signal can be explained by changes in RPE cells, such as increased intracellular concentration of lipofuscin, loss of protective melanosomes, RPE dysmorphia resulting in taller cells or RPE migration leading to stacked cells. 7, 8 Genetic and biochemical studies have found that AMD is related to dysregulation of the innate immune system, mainly involving complement factors, monocytes, macrophages and microglia. 9 Migration of systemic immune cells into the choroid and retina has been shown to be present at all stages, but particularly in late stages of AMD. 10, 11 These infiltrating cells and the broad alterations of systemic immune cells suggests the involvement of the adaptive immune system in AMD and supports the notion of AMD as a systemic disease. In patients with neovascular AMD we previously found neutrophils with an altered activation state, 12 lower frequency of T-helper 1 cell 13 and aged phenotype of cytotoxic T-cells.
14 Furthermore, natural killer cells are demonstrated to promote CNV formation, 15 and B cells from donors with AMD tend to be more sensitive to antigen-stimulation. 16 Under normal conditions, microglia serves as the resident immune cells in the central nervous system (CNS) and in the retina, protecting the neurons from damage. Young microglia have a ramified morphology, and are evenly distributed in the inner layers of the retina. 17 In the young retinal tissue, the area from the outer plexiform layer to the subretinal space is clear of microglia cells. In the aged retina, microglia infiltrate and accumulate in the subretinal space right next to the RPE cells. 18 Under pathological conditions microglia cells are activated and transform into an amoeboid phenotype with phagocytic capabilities, producing pro-inflammatory cytokines, chemokines, nitric oxide and reactive oxygen species. 18, 19 The dynamics of the shift from resting microglia and the re-distribution in response to activation are thought to be controlled by chemokine signalling, especially CCL2-CCR2 and CX3CL1-CX3CR1, as elaborated in animal studies demonstrating that CX3CR1 −/− and CCL2 −/− mice develop an accelerated age-related accumulation of activated subretinal microglia or macrophage cells. 20, 21 These pathways are of particular relevance in age-related diseases, since human aging leads to decreased monocyte CX3CR1 expression, and increased plasma CCL2 concentration. 22 Inappropriate microglia activation plays a central part in neurodegenerative diseases, as the microglia-mediated inflammatory response ultimately contributes to increased neuron-damage. 23, 24 In cases of RPE injury, microglia are mobilized from the inner retina to the RPE, before monocyte infiltration from the blood. 25 Blood monocytes and microglia share the same origin of myeloid lineage; they show similar antigens, functions and regulatory mechanisms. 26 The CD200 receptor (CD200R) is found on the surface of myeloid cells, including microglia. 27 The ligand, CD200, is a surface glycoprotein found on neurons and on myeloid cells. 28 Stimulation of CD200R on myeloid cells, leads to downregulation, and has the potential of suppressing neuroinflammation through stimulation of microglia. 29 In this way, CD200-CD200R interaction has neuroprotective properties. 30 These findings were supported by animal studies, where CD200-deficient mice displayed normal retinal microglia morphology, but demonstrated an increased microglia response, increased myeloid cell infiltration, and a continued increased photoreceptor cell apoptosis after stimulation. 31 Microglia, monocytes and CD200 are well described in their role of central neuroinflammation and neurodegeneration. Interestingly, peripherally induced inflammation leads to inflammation in CNS, with a rapid upregulation of both CD200 and CD200R. The same study showed that monocyte-depletion significantly decreased the responsive neuroinflammation. 32 Monocytes in human blood are heterogeneous and can be divided into three distinct subsets described on the expression of phenotypic markers. These cells are referred to as classical monocytes (CD14+ CD16−), intermediate monocytes (CD14+ CD16+), and non-classical monocytes (CD14 low CD16+). 33, 34 To describe the potential role of monocyte functional subset, we assessed the proportion of CD200+ cells in each monocyte subset. Disturbances in CD200:CD200R regulation can potentially lead to exaggerated activated microglia, which subsequently migrate to the subretinal space 35 and cause phagocytosis of damaged retinal tissue. 36, 37 Previously, we have found an increase in CD200+ monocytes in patients with neovascular AMD, but no change in CD200R. 38, 39 To shed light on the potential dysregulation of myeloid activation in GA, we examined the expression levels of CD200 on circulating monocytes in patients with GA and studied CD200 expression in patients with different risks of progression.
METHODS Design
This was a prospective case-control study, where we compared monocytic CD200 expression of patients with GA to that of healthy age-matched controls. The protocol was approved by the Regional Committee of Ethics in Research of the Region of Zealand (SJ-385). Oral and written informed consent was obtained from all participants prior to inclusion. The project adhered to the tenets of the Declaration of Helsinki.
Study participants and inclusion
Patients were recruited from our retinal outpatient program, during a period of 18 months. Patient spouses accompanying them in the clinic were recruited as healthy controls. This recruitment strategy served to match the groups in demographic and lifestyle factors. Individuals were not included if they had any current infectious disease, immunological disorders, cancer, or if they received immunemodulating medication. All participants had measured C-reactive protein (CRP), and were excluded post hoc if CRP > 15 mg/L since this was interpreted to reflect an ongoing infection or acute systemic inflammation. 40 All included participants were subjected to a structured interview regarding health, past medical history, medication, tobacco and alcohol use. Smoking habits were categorized as current smokers, former smokers (ceased smoking over a year ago) or never smokers (less than 100 cigarettes in their lifetime). 41 Alcohol consumption was registered as self-reported amount of units (12 g ethanol) per week. Height and weight was used to calculate body mass index. Physical activity was quantified using a single question, which has been validated in patients with AMD. 42, 43 Since no previous studies have investigated CD200 in patients with GA, we based our power calculations on a study of CD200 in patients with neovascular AMD 38 which we considered the best possible approximation for the purpose. We transferred values to mean and standard deviation using recommendations from the Cochrane Handbook (mean = median, standard deviation = interquartile range/1.35) 44 and assumed a significance value of 0.05 and a power of 80%. This exercise suggested that we need 26 individuals in each group. We therefore recruited at least 26 individuals in each group, but allowed further recruitment of patients with GA during the study period to allow explorative investigations into FAF subtypes in patients with GA.
Retinal diagnosis
Examination including best corrected visual acuity, slit-lamp examination, indirect dilated fundoscopy, spectral domain optical coherence tomography (OCT) and FAF (Heidelberg Engineering, Heidelberg, Germany) were performed in each case. Fluorescein and indocyanine green angiographies were performed in cases of suspected neovascularization to rule out any cases with neovascular AMD. Patients with GA had drusen and one or more welldefined atrophic area in the macula region visible by fundoscopy, FAF and OCT. Patients with GA had no neovascularizations in either eye and no history of neovascular AMD. Patients with subretinal fibrosis or any other sign of former neovascularization were not included. Healthy controls had less than 10 small drusen (<63 μm) and did not suffer from any retinal diseases.
Grading of geographic atrophy and progression analysis
FAF images were acquired using Blue light autofluorescence 30 × 30 centred at the fovea using Heidelberg Spectralis (Heidelberg Engineering, Heidelberg, Germany). Images were captured with an excitation wavelength of 488 nm and an emission spectrum of 500-700 nm. Resolution mode was set to high speed, with a resolution of 768 × 768 pixels. Single FAF images were aligned automatically to reduce noise using the manufacturer's software.
GA patients were stratified into subgroups according to the degree of hyperautofluorescence on CD200 expression in geographic atrophyFAF images. In 2007, Holz et al. introduced the grading categories: none, focal, banded, patchy and diffuse. 6 They identified pattern type none as no increased FAF signal in the junctional zone of atrophy. Pattern type focal has single or individual small spots of increased FAF signal adjacent directly to the margin of GA. Pattern type banded has a continuous ringshaped increased FAF signal around GA. Pattern type patchy is a laminar homogeneous hyperautofluorescence. Pattern type diffuse has hyperautofluorescence at the margin of the atrophy and elsewhere in the macular area. Holz et al. identified that the none and the focal pattern types predict a slow progression rate, whereas the banded and the diffuse pattern types predict a fast progression rate. Biarnés et al. has since suggested a simplified classification that combined none and focal into one category (slow progressors), and banded and diffuse into one category (fast progressors). 45 This method improved reproducibility of grading. In this study, we chose to follow the simplified Biarnés et al. classification since our aim was to explore possible differences between slow and fast progressors.
Two investigators with experience in evaluation of FAF images (MKN and MF) independently performed the grading of the baseline FAF images blinded from any clinical, demographic and immunological information. In cases of disagreement, a third investigator (TLS) was involved and majority ruled. In this cohort we did not have any patients with the patchy pattern type. Examples of pattern types are presented in Figure 1 .
To verify that banded and diffuse pattern types indeed predicted fast progression and that none and focal pattern types indeed predicted slow progression, we repeated GA lesion measurement after 12 months to calculate the progression rate of the GA lesion. All patients were invited to follow-up 12 months after inclusion. The total size of uni-or multifocal lesions were measured by outlining of the dark areas in the FAF image using image analysis software (RegionFinder, Heidelberg Eye Explorer, Heidelberg, Germany). The area change during one year was registered as shown in Figure 1 . 
Blood sampling and flow cytometry
Each participant had blood sampled from the antecubital vein in two vacutainer tubes, one 5 mL for flow cytometry containing ethylenediaminetetraacetic acid coagulant, and one 3 mL for plasma CRP measurement containing lithiumheparin. All analyses were initiated within 4 h of phlebotomy. Based on the leukocyte count measured (Sysmex KX-21N, Sysmex Corporation, Kobe, Japan), we calculated a volume equivalent to 5 × 10 5 leukocytes to estimate the volume of antibodies required for the sample. Whole blood was lysed for 10 min in the dark at room temperature by adding red blood cell lysis buffer (Nordic Biosite AB, Täby, Sweden). Cells were washed three times by centrifuging for 5 min by 500G, decanting the supernatant, and resuspending in isotonic buffer (IsoFlow Sheath Fluid, Beckman Coulter Inc., Brea, CA, USA). The following monoclonal antibodies were added to the leukocytes: Phycoerythrin-CY7 CD14, IgG2a κ, 
Data analysis and statistics
Flow cytometry data was analysed using Kaluza Analysis (Kaluza Analysis version 1.5.20365.16139, Brea, CA, USA). Analysis was performed by two individual investigators (author MKN and YS), blinded from diagnosis or any clinical information. Gating strategy is presented in Figure 2 . First we isolated singlets and from cell size and complexity (forward scatter/side scatter) we determined monocytes. Monocytes were since categorized into subgroups based on their expression of CD14 and CD16. Negative isotype control was used to determine the percentage of CD200 positive monocytes.
Statistical analysis was performed using SPSS version 24 (IBM Corporation, Armonk, NY, USA) and presented using GraphPad Prism 7 (GraphPad Software, La Jolla, CA, USA). Normally distributed data was presented in mean and standard deviation (SD) and compared using parametrical tests. Not normally distributed data was presented using median and interquartile range (IQR) and compared using non-parametrical tests. Categorical data was Figure 2 . Monocyte gating strategy and expression analysis. We isolate singlets (a) and from cell size, complexity and HLA-DR expression, we determine the monocytes (b,c). Monocyte subgroups are determined based on expression levels of CD14 and CD16 (d). The proportion of CD200+ cells were then detected using antibody corresponding negative isotype control, gate set at 1% (e). Abbreviations: FSC, forward scatter; SSC, side scatter; A, area, H, height.
presented in percentages and tested using χ 2 test, unless sample size was small (<5 cases) in which case the more appropriate Fisher's exact test was used.
All participants included were compared on selected relevant parameters. The distribution of monocytes and expression levels of CD200 were determined and compared across the groups. P values below 0.05 was considered statistically significant.
RESULTS Participants
A total of 74 participants were recruited. The group consisted of 47 patients with GA and 27 healthy age-matched adults. All participants were of Caucasian descent. Two participants (one patient with GA and one healthy control) were excluded from analyses due to elevated plasma CRP (>15 mg/L).
Our patients with GA and control individuals did not differ significantly in terms of demographics and lifestyle factors (Table 1) . Patients with GA had a higher prevalence of hypertension and cardiovascular disease, which are both known associated comorbidities.
GA patterns and progression profile
We analysed FAF as described in Section 2.4, and compared patients with slow or fast progression profile. We found that 22 patients had the none or focal pattern type, and 24 patients had the banded or diffuse pattern type. These groups did not differ significantly in demographics, lifestyle factors or prevalence of comorbidities.
Cohen's kappa coefficient was calculated to determine the level of agreement between the two graders in evaluating FAF images. There was an excellent agreement between the graders, κ = 0.917, P < 0.001.
We followed our cohort to confirm that the patients enrolled was in fact fast or slow progressors. We examined them 1 year later to measure their progression rate in 1 year. Ninety four percent of the patients enrolled came back for follow-up examination. We found that those with pattern types none and focal had a progression rate median of 0.95 mm 2 /year (IQR: 0.48-1.60), whereas those with pattern types banded and diffuse had a progression rate median of 2.03 mm 2 /year (IQR: 1.58-2.88). The difference between the two groups was significant (P < 0.001, Mann-Whitney U test).
CD200 expression
We measured the expression levels of CD200 on monocytes overall, and in monocyte subsets. Patients with GA had a significantly higher percentage of CD200+ monocytes overall (P = 0.048, MannWhitney U) and in each subgroup (Fig. 3) . We performed a logistic regression analysis which showed that CD200 expression was independent of copresence of hypertension (P = 0.530), cardiovascular disease (P = 0.773) or type II diabetes (P = 0.339) in the study population.
We subsequently repeated the analysis on GA patients stratified by hyperautofluorescence patterns. In this comparison, patients with a high degree of hyperautofluorescence, and a fast progression profile, had higher levels of CD200+ monocytes compared to that of patients with GA and low degree of hyperautofluorescence (P = 0.024, Mann-Whitney U), this was also the case in monocyte subsets as presented in Figure 4 . 
DISCUSSION
In this study, we find that patients with GA have a significant higher percentage of CD200+ monocytes, when compared to healthy controls. Monocyte infiltration is closely associated to late stage AMD, and with microglial behavior. 24 The role of microglia is protection from neuronal harm. In the aged CNS, the microglia-mediated response to harm is exaggerated; inappropriate in magnitude, and prolonged in duration. This generates a larger inflammatory response and a worse functional outcome than in the young. 46, 47 In this way, the inflammation and phagocytosis of damaged retinal tissue might work harmfully in the case of GA. In increasing age, the density of microglia in both the inner and outer plexiform layer is increased. 48 Specifically, in retinas from patients with GA, the amoeboid phenotype of microglia is found within the nuclear layers, and these cells are active phagocytes of photoreceptor debris.
49 CD200 provides a down-regulating signal affecting microglia activity. 50 In this study, we examined CD200 on circulating monocytes, as we have previously found these levels altered in two cohorts of patients with neovascular AMD. 38, 39 Dysfunctions in the CD200:CD200R axis might lead to microglial activation and neurodegeneration, 51 and over-activated microglia is very likely to play a central role in late stage AMD. The down-regulating mechanism through CD200:CD200R interaction has been demonstrated in neurodegenerative diseases. It has been implied that the CD200R1 agonist, CD200 fusion protein, can countermeasure age-related microglia-activation and balance the inflammatory reaction caused by microglia-activation, and suppress the development of neurodegenerative diseases. 52, 53 The increase in CD200 expression in patients with GA might imply a general imbalance, where despite an increased down-regulating signal, microglia is chronically activated, and works unhampered, spreading inflammatory cytokines and consuming retinal cells. Another possibility is that other mechanisms upregulate microglia activity, causing the disease activity, and that the higher expression of CD200 is the immune system's counteractive response. Aged microglia accumulates intracellular lipofuscin, detectable in FAF images. 18, 45 This accumulation of lipofuscin, that shares characteristics of RPE lipofuscin, is possibly responsible for the change in microglia morphology and activity state. Ma et al. has demonstrated that cultured retinal microglia internalizes exogenous A2E, a bis-retinoid consisting of ocular lipofuscin. 50 Subsequently, the microglia cells shifts into a more activated morphology with a pro-inflammatory gene expression profile, as well as expression of complement regulatory proteins. The study by Ma et al. reveal that the A2E-loaded, pro-complement phenotype induce deposition of complement factor C3 activation products and that the increased complement deposition in these eyes corresponded to a significantly elevated level of photoreceptor apoptosis. More studies find associations between microglia and complement activity, and that activated microglia is capable of complement synthesis. 35, 54 This seems to be a two-way street, as convincing research has suggested that Complement Factor H is a necessary factor to the pathogenic subretinal accumulation of mononuclear phagocytes and resolution of inflammation. 55 Also, complement anaphylatoxin signalling, especially C5a, is an efficient upregulator of microglia activity. 56, 57 Mice with knockout of C3a, but not C5a show progressive retinal cell loss and decreased function following light stimuli, supporting a role for C5a in microglia activation and following phagocytosis of retinal cells. 58 This gives strong indications that the lipofuscin visible on FAF is internalized in aged microglia cells, causing the inappropriate activation-state. This could result in apoptosis and phagocytosis of retinal tissue, leading to development and progression of GA. In the results presented here, we find that the regulatory molecule CD200 associates with the degree of hyperautofluorescence seen on FAF representing levels of lipofuscin.
Important limitations should be considers when interpreting the results. Due to the observational character of this study, we are unable to prove causality. Peripheral immune-regulation of microglia activity is challenging to interpret, and this study does not show if in fact the findings are part of disease mechanism, or an immunological neuroprotective response to disease. In this description of the CD200:CD200R axis we solely described expression of CD200, and not its receptor. Although we previously found no alteration in the CD200R expression in patients with neovascular AMD, 38 it can be argued that expression data on CD200R in patients with GA with no CNV could provide further insight to disease mechanisms. Finally, the emission spectrum for autofluorescence in retinal microglia cells resembles that for RPE containing lipofuscin 15 and therefore they cannot be differentiated.
In conclusion, we find that a higher proportion of monocytes express the microglia regulator CD200 among patients with GA, and that monocyte CD200 positivity associates well with accumulated lipofuscin surrounding the macular atrophic area. Our findings suggest that CD200 is a biomarker of a fast disease progression. Age-related changes in the myeloid cell lineage causes alterations in the retinal microenvironment, giving rise to the agedependency in AMD. This might mean that GA holds important similarities with neurodegenerative diseases in microglial dysregulation, and that the understanding of microglial behaviour and regulation mechanisms are beneficial in order to potentially use these cells as therapeutic targets.
